GTS Securities’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-188,800
Closed -$2.38M 3145
2024
Q3
$2.38M Sell
188,800
-85,800
-31% -$1.11M 0.01% 1445
2024
Q2
$3.48M Buy
274,600
+111,200
+68% +$1.12M 0.01% 1102
2024
Q1
$781K Sell
163,400
-152,500
-48% -$707K ﹤0.01% 2178
2023
Q4
$1.52M Sell
315,900
-211,600
-40% -$1.3M ﹤0.01% 1852
2023
Q3
$3.82M Buy
+527,500
New +$4.21M 0.01% 1089

Other funds holding NVAX

GTS Securities's NVAX Position: Q4 2024 in Review

GTS Securities sold out of Novavax (NVAX) in Q4 2024, closing a stake of 46,501 shares — an estimated $587K sold.

GTS Securities first reported a position in NVAX in Q3 2023 and held it in 2 quarters. The position peaked at $587K in Q3 2024. 234 funds tracked by Wall St. Rank hold NVAX as of Q4 2024.

  • GTS Securities reported no remaining Novavax position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 46,501 Novavax shares in Q4 2024, an estimated $587K.
  • GTS Securities first reported a position in Novavax in Q3 2023 and held it in 2 quarters.
  • GTS Securities's Novavax position peaked at $587K in Q3 2024.
  • 234 funds tracked by Wall St. Rank held Novavax as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.